REGENXBIO To Participate In Upcoming Investor Conferences

(MENAFN- PR Newswire)

ROCKVILLE, Md., March 2, 2026 /PRNewswire/ – REGENXBIO Inc. (Nasdaq: RGNX ) today announced it will participate in the following investor conferences:

** Leerink Partners Global Healthcare Conference
** ** Fireside Chat:** Monday, March 9 at 9:20am ET
** Location:** Miami, FL

** Barclays 28th Annual Global Healthcare Conference
** ** Fireside Chat:** Tuesday, March 10 at 1:30pm ET
** Location:** Miami, FL

** RBC Inaugural Virtual Ophthalmology Conference
Fireside Chat:** Tuesday, March 24 at 8:45am ET **
Location:** Virtual

Live webcasts of select events can be accessed in the Investors section of REGENXBIO’s website at . Archived replays of the webcasts will be available for approximately 30 days following the events.

** ABOUT REGENXBIO Inc.
** REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO’s AAV platform, including those receiving Novartis’ ZOLGENSMA®. REGENXBIO’s investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit.

** Contacts:
** Dana Cormack
Corporate Communications
[email protected]

Investors:
George E. MacDougall
Investor Relations
[email protected]

SOURCE REGENXBIO Inc.

21% more press release views with Request a Demo

MENAFN03032026003732001241ID1110808812